IIN Inion Oy

RNS Number:7943S
Inion Oy
18 October 2005





         SA SpineVision litigation dismissed by French Commercial Court


Tampere, Finland and Takeley, UK. 18th October 2005...Inion Oy (LSE: IIN.L) ("
Inion"), a rapidly growing company focused on the development of novel
biodegradable medical implants, has successfully defended a court action brought
by SA SpineVision ("SpineVision") in the Commercial Court of Paris.



Inion and SpineVision signed a confidentiality agreement in October 2002 with a
view to exploring the possibilities of a joint development in the spinal area.
However, no contractual agreement was reached and in October 2003 Inion decided
not to pursue the relationship any further. In January 2004 SpineVision served a
writ alleging unfair termination of contractual relations and seeking damages of
around Euro9 million.



When Inion carried out its Initial Public Offering in 2004, this action was
identified as a risk factor. In the listing particulars the directors of Inion
stated that they believed the claim to be unfounded.



In defending the case Inion asked for the Paris Commercial Court to rule itself
unfit to hear the case and entered a counter claim against SpineVision.



The judgement given by Mr Miffre, Presiding Judge on 4th October 2005, and
received in writing by the Company on 17 October, was as follows:



 1. The Commercial Court of Paris disclaims competence in favour of another court
 2. SA SpineVision is ordered to pay Inion's court and legal costs



Dr Auvo Kaikkonen, CEO of Inion commented, "We are very pleased to receive this
ruling from the Commercial Court of Paris. The ruling demonstrates our resolve
to protect our intellectual property to the maximum extent permissible in law."





                                     -Ends-



For further information, please contact:


Inion Oy
Dr Auvo Kaikkonen, Chief Executive Officer             +358 3 230 6600
Tim Hirst, Corporate Communications                    +44 (0)1279 874 222

Citigate Dewe Rogerson
Mark Swallow / Helena Podd                             +44 (0)20 7638 9571



About Inion (www.inion.com)

Inion Oy is a Finnish company that specialises in the development of
biodegradable medical implants. Inion's core expertise and technology lies in
the design and manufacture of innovative biodegradable plates, screws, pins and
membranes that are used to enhance the healing of skeletal injuries (bone and
soft tissue), such as those caused by trauma or by reconstructive surgery.
Inion's implants are made from its proprietary OPTIMA(TM) family of
biomaterials, with properties tailored for specific surgical applications, in
terms of strength, flexibility and rate of degradation.



Inion has developed and launched products in four strategic business areas -
cranio-maxillofacial surgery, orthopaedic trauma, sports medicine and dental
surgery - in more than 40 countries worldwide, and has a number of international
distribution agreements in place, with among others Stryker Corporation and
Aesculap (part of B.Braun).



Inion was incorporated in early 2000 by an international team of experts in
biodegradable materials and their clinical applications, and listed on the
Official List of the UK Listing Authority in December 2004 (LSE: IIN). The
Company's has corporate headquarters in the UK, R&D and production facilities in
Tampere, Finland, and a US office in Oklahoma City, OK.



This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions
or the negative thereof. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or achievements of the
Group to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions regarding the
Group's present and future business strategies and the environment in which the
Group will operate in the future. Among the important factors that could cause
the Group's actual results, performance or achievements to differ materially
from those in forward-looking statements include those relating to Inion's
funding requirements, regulatory approvals, reliance on third parties,
intellectual property, key personnel and other factors. These forward-looking
statements speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained in this announcement to reflect any
change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, prospective investors are cautioned not to rely on any
forward-looking statement.







                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCGGMMGLNVGKZM

Inion Oy (LSE:IIN)
Historical Stock Chart
From Jul 2024 to Aug 2024

Inion Oy (LSE:IIN)
Historical Stock Chart
From Aug 2023 to Aug 2024